GAMMA Investing LLC Has $209,000 Stock Position in Bio-Techne Co. (NASDAQ:TECH)

GAMMA Investing LLC grew its holdings in shares of Bio-Techne Co. (NASDAQ:TECH) by 13.0% in the 4th quarter, Holdings Channel reports. The fund owned 2,896 shares of the biotechnology company’s stock after buying an additional 333 shares during the period. GAMMA Investing LLC’s holdings in Bio-Techne were worth $209,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in TECH. Versant Capital Management Inc lifted its stake in shares of Bio-Techne by 35.0% in the 4th quarter. Versant Capital Management Inc now owns 763 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 198 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of Bio-Techne by 0.7% during the third quarter. Principal Financial Group Inc. now owns 261,900 shares of the biotechnology company’s stock valued at $20,934,000 after purchasing an additional 1,843 shares in the last quarter. Oddo BHF Asset Management Sas acquired a new position in shares of Bio-Techne in the third quarter valued at approximately $1,188,000. Synovus Financial Corp boosted its position in Bio-Techne by 1.5% during the 3rd quarter. Synovus Financial Corp now owns 13,223 shares of the biotechnology company’s stock worth $1,057,000 after buying an additional 198 shares during the period. Finally, Tidal Investments LLC grew its holdings in Bio-Techne by 17.7% during the 3rd quarter. Tidal Investments LLC now owns 28,940 shares of the biotechnology company’s stock worth $2,313,000 after acquiring an additional 4,356 shares during the last quarter. Institutional investors own 98.95% of the company’s stock.

Bio-Techne Stock Up 0.7 %

Shares of Bio-Techne stock opened at $74.77 on Wednesday. The stock’s 50-day moving average is $73.88 and its 200 day moving average is $74.17. Bio-Techne Co. has a one year low of $61.16 and a one year high of $85.57. The firm has a market cap of $11.88 billion, a price-to-earnings ratio of 79.54, a PEG ratio of 5.52 and a beta of 1.27. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.56 and a quick ratio of 3.26.

Bio-Techne (NASDAQ:TECH) last posted its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.38 by $0.04. The firm had revenue of $289.46 million for the quarter, compared to analysts’ expectations of $280.22 million. Bio-Techne had a return on equity of 12.76% and a net margin of 12.86%. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the prior year, the business earned $0.35 EPS. Equities research analysts anticipate that Bio-Techne Co. will post 1.68 EPS for the current year.

Bio-Techne Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 22nd. Stockholders of record on Monday, November 11th were issued a dividend of $0.08 per share. The ex-dividend date of this dividend was Friday, November 8th. This represents a $0.32 annualized dividend and a dividend yield of 0.43%. Bio-Techne’s dividend payout ratio is currently 34.04%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the stock. StockNews.com upgraded shares of Bio-Techne from a “hold” rating to a “buy” rating in a report on Tuesday, November 12th. Scotiabank upped their price target on Bio-Techne from $83.00 to $88.00 and gave the company a “sector outperform” rating in a research report on Thursday, October 31st. Finally, Robert W. Baird raised their price objective on Bio-Techne from $82.00 to $84.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $82.00.

Bio-Techne Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.